Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780579 | 0.86 | TDP1 (0.46) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL1679925 | 0.83 | MAPT (0.43) | MEN1KMT2AMAPTL3MBTL1GAA | |
| SCHEMBL29729282 | 0.80 | MEN1 (0.54) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL874114 | 0.80 | MEN1 (0.54) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL2089147 | 0.80 | MEN1 (0.54) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL1679907 | 0.79 | L3MBTL1 (0.41) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL12310509 | 0.77 | ALDH1A1 (0.54) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL29172544 | 0.76 | MEN1 (0.48) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL12118843 | 0.76 | MEN1 (0.47) | MEN1KMT2AMAPTLMNAPKM | |
| SCHEMBL1679874 | 0.74 | MAPT (0.40) | MAPTL3MBTL1NPC1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367833-B2 | Process for producing 6-aryloxyquinoline derivative and intermediate therefor | NIPPON KAYAKU CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20110118468-A1 | PROCESS FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREFOR | MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118468-A1 | PROCESS FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREFOR | FAR1, CYP4F11, WEE2 | MEN1 2109/4885KMT2A 902/4885MAPT 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.